TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03072433

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling Intervention Package
Description: Daily 45 minutes of group teaching for primary caregivers, followed by 45 minutes of supervised play and stimulation with their children for a total of four days. Teaching modules consist of psychosocial stimulation, nutrition and feeding, and water, sanitation and hygiene practices.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Nutrition and water sanitation and hygiene counseling at any point prior to discharge from hospital as per the local nutrition rehabilitation unit standard of care. In addition, primary caregivers will be stimulated to play with their children in a play area.
Study: NCT02851771

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal Swab
Study: NCT00105768

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Advisor-Teller Money Management-Substance Abuse Counselling
Study: NCT03198065

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hand-made glove setting
Description: The patients receive Hand-made glove setting for single-incision laparoscopic appendectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Commercialized single-incision multiport setting
Description: The patients receive commercialized single-incision multiport setting for single-incision laparoscopic appendectomy
Study: NCT03973528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: traditional Chinese medicine: tonifying kidney Wan
Description: traditional Chinese medicine : tonifying kidney Wan
Study: NCT03914963

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fibrin sealant hemipelvis
Description: Following the manufacturer´s instructions, 5 ml of sealant was sprayed evenly across the entire surgical bed in only one hemipelvis (the treated hemipelvis) after pelvis bilateral lymphadenectomy.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Control hemipelvis
Description: Contralateral hemipelvis not treated with fibrin sealant
Study: NCT04145349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Administered IV
Study: NCT01025895

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: acle reconstruction - single bundle technique
Study: NCT06114459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Chloride
Description: Post surgery disinfection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Chloride
Description: Post surgery disinfection
Study: NCT04339140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zafirlukast
Description: Oral tablets, 2x daily for 28 day cycle up to 1 year
Study: NCT03960463

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcu O2®
Description: Participants randomized into study active group will be provided with a Transcu O2® at their surgical site and followed for 4 weeks.
Study: NCT05099029

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EV71 vaccine
Description: EV71 vaccine (\[1 μg total protein + adjuvant 150 μg AI(OH)3\] per dose) Two vaccinations at 28 days apart
Study: NCT02311361

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 10 mg/kg, mg intravenous (IV), every two weeks, or 1500 mg, IV, every four weeks.
Study: NCT05099029

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (\[ adjuvant 150 μg AI(OH)3\] per dose) Two vaccinations at 28 days apart
Study: NCT02311361

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 10 mg/kg, mg intravenous (IV), every two weeks, or 1500 mg, IV, every four weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 10 mg/kg, mg intravenous (IV), every two weeks, or 1500 mg, IV, every four weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 10 mg/kg, mg intravenous (IV), every two weeks, or 1500 mg, IV, every four weeks.
Study: NCT03062839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg
Description: Melatonin 5 mg taken 30 minutes before bed time

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Melatonin 5 mg
Description: Melatonin 5 mg taken 30 minutes before bed time
Study: NCT03182712

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: n-3 PUFA Group
Description: Participants received n-3 PUFA capsules (capsules containing 180 mg of eicosapentaenoic acid, 120 mg of docosahexaenoic acid and 2 mg of vitamin E). Three capsules were ingested daily for eight weeks, distributed between breakfast, lunch and dinner.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: Participants received capsules containing 500 mg of gelatin.Three capsules were ingested daily for eight weeks, distributed between breakfast, lunch and dinner.
Study: NCT01615718

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: low-intensity transcranial electrical stimulation
Description: Subjects will undergo 20 minutes of low-intensity transcranial electrical stimulation of up to 2mA. During active stimulation, the current will be active for 20 minutes - however, during sham stimulation (placebo) the current will not be active for the full 20 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: low-intensity transcranial electrical stimulation
Description: Subjects will undergo 20 minutes of low-intensity transcranial electrical stimulation of up to 2mA. During active stimulation, the current will be active for 20 minutes - however, during sham stimulation (placebo) the current will not be active for the full 20 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: low-intensity transcranial electrical stimulation
Description: Subjects will undergo 20 minutes of low-intensity transcranial electrical stimulation of up to 2mA. During active stimulation, the current will be active for 20 minutes - however, during sham stimulation (placebo) the current will not be active for the full 20 minutes.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: low-intensity transcranial electrical stimulation
Description: Subjects will undergo 20 minutes of low-intensity transcranial electrical stimulation of up to 2mA. During active stimulation, the current will be active for 20 minutes - however, during sham stimulation (placebo) the current will not be active for the full 20 minutes.
Study: NCT04304599

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LoFric Elle
Description: The study device is commercially available (CE-marked). It is a device for female intermittent catheterization. Treatment Period will last for 2 weeks. The angulated handle available with the device must be used by each subject at least 10 times.
Study: NCT03570164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: End-tidal concentration of sevoflurane is maintained at age-corrected 1.0 minimum alveolar concentration throughout the study period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Description: End-tidal concentration of desflurane is maintained at age-corrected 1.0 minimum alveolar concentration throughout the study period.
Study: NCT01563614

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brain radiotherapy (WBRT alone, SRT/SRS alone or WBRT plus SRT/SRS)
Description: Brain radiotherapy concomitant to lomustine and liposomal cytarabine chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lomustine
Description: Brain radiotherapy concomitant to lomustine and liposomal cytarabine chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal cytarabine
Description: Brain radiotherapy concomitant to lomustine and liposomal cytarabine chemotherapy.
Study: NCT01483339

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metacognitive Therapy
Description: Metacognitive Therapy for OCD according to Wells (1997)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure and Response Prevention
Description: Exposure and Response Prevention for OCD according to Kozak \& Foa (1997)
Study: NCT00900887

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: ophthalmic presentation 5 mg/ml dosage one drop (0.25 mg) in the treated eye 3 times a day during one week
Study: NCT02311361

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: 75 mg IV, every 4 weeks for 16 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: 75 mg IV, every 4 weeks for 16 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: 75 mg IV, every 4 weeks for 16 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: 75 mg IV, every 4 weeks for 16 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Sterostatic body radiation therapy (SBRT)
Description: 8 Gray (Gy) x 1; 5Gy x 5

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Sterostatic body radiation therapy (SBRT)
Description: 8 Gray (Gy) x 1; 5Gy x 5

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Sterostatic body radiation therapy (SBRT)
Description: 8 Gray (Gy) x 1; 5Gy x 5

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Sterostatic body radiation therapy (SBRT)
Description: 8 Gray (Gy) x 1; 5Gy x 5

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Sterostatic body radiation therapy (SBRT)
Description: 8 Gray (Gy) x 1; 5Gy x 5
Study: NCT04218370

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dialysis
Description: Dialysis treatment, either in the form of hemodialysis or continuous renal replacement therapy (if patient develops hemodynamic instability)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dialysis
Description: Dialysis treatment, either in the form of hemodialysis or continuous renal replacement therapy (if patient develops hemodynamic instability)
Study: NCT02311361

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Sterostatic body radiation therapy (SBRT)
Description: 8 Gray (Gy) x 1; 5Gy x 5
Study: NCT02388971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN1202
Description: MLN1202 solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: MLN1202 placebo-matching solution
Study: NCT02775045

Intervention type: OTHER
Intervention: Observation Period
Description: 8 week observational period
Study: NCT02149420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAY736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAY736

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01442753

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family-Skills Training
Description: Sessions will be divided between self-reflection, didactics, and skill-building exercises all aimed at developing strong parenting practices and facilitating relationship building between parents and youth.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family-Skills Training
Description: Sessions will be divided between self-reflection, didactics, and skill-building exercises all aimed at developing strong parenting practices and facilitating relationship building between parents and youth.
Study: NCT01646554

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modified FOLFOX6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified FOLFOX6

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Targeted therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Study: NCT01615718

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transcranial ultrasound
Description: Subjects will undergo 20 minutes of transcranial ultrasound. During active stimulation, the ultrasound will be active for 20 minutes - however, during sham stimulation (placebo) the ultrasound will not be active for the full 20 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial ultrasound
Description: Subjects will undergo 20 minutes of transcranial ultrasound. During active stimulation, the ultrasound will be active for 20 minutes - however, during sham stimulation (placebo) the ultrasound will not be active for the full 20 minutes.
Study: NCT00772239

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rotation thromboelastometry (ROTEM)
Description: Coagulation measurement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard coagulation managment procedure
Description: Standard coagulation managment procedure
Study: NCT04036539

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placement of the mini-implant and verticalization
Description: an orthodontic mini-implant will be installed in the retromandibular region. The site will be anesthetized. The region will be pre-drilled by about 5mm with a spear drill attached to an implant motor. Once the mini-implant has been selected, it will be locked into position using a kit-specific digital key. Being threaded clockwise until the intramucosal mini-implant is at the gingival level. After installation, a metallic orthodontic lingual will be glued to the molar mesial to be verticalized. The lingual button will be glued to the inclined molar mesial with orthodontic adhesive. A gray chain elastomeric ligature will attach the head of the mini-implant to the lingual button glued to the molar mesial. A light force of 150gr will be imposed (measured with a tensiometer) in all cases, regardless of tooth position. This chain elastic will be changed every 30 days for a period of 3 months. After 90 days of the experiment time, the mini-implants will be removed.
Study: NCT01615718

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial ultrasound
Description: Subjects will undergo 20 minutes of transcranial ultrasound. During active stimulation, the ultrasound will be active for 20 minutes - however, during sham stimulation (placebo) the ultrasound will not be active for the full 20 minutes.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: transcranial ultrasound
Description: Subjects will undergo 20 minutes of transcranial ultrasound. During active stimulation, the ultrasound will be active for 20 minutes - however, during sham stimulation (placebo) the ultrasound will not be active for the full 20 minutes.
Study: NCT04036539

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placement of the mini-implant and verticalization
Description: an orthodontic mini-implant will be installed in the retromandibular region. The site will be anesthetized. The region will be pre-drilled by about 5mm with a spear drill attached to an implant motor. Once the mini-implant has been selected, it will be locked into position using a kit-specific digital key. Being threaded clockwise until the intramucosal mini-implant is at the gingival level. After installation, a metallic orthodontic lingual will be glued to the molar mesial to be verticalized. The lingual button will be glued to the inclined molar mesial with orthodontic adhesive. A gray chain elastomeric ligature will attach the head of the mini-implant to the lingual button glued to the molar mesial. A light force of 150gr will be imposed (measured with a tensiometer) in all cases, regardless of tooth position. This chain elastic will be changed every 30 days for a period of 3 months. After 90 days of the experiment time, the mini-implants will be removed.
Study: NCT03400020

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ascorbic acid
Description: Ascorbic acid 500 Mg in normal saline IV two hours before the operation and thereafter 500 mg in normal saline IV daily for three days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal saline IV two hours before the operation and thereafter for three days.
Study: NCT04776772

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synbiotic complement
Description: On two separate days, the baseline-tests and final-tests were conducted. All participants performed a series of tests, before which they had to fast. The order and schedule (8 am) of the tests was the same for the final-test and the same materials and procedures were used. A period of 30 consecutive days elapsed between the base-line and final tests, during which the participants had to ingest their supplement (synbiotic).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Synbiotic complement
Description: On two separate days, the baseline-tests and final-tests were conducted. All participants performed a series of tests, before which they had to fast. The order and schedule (8 am) of the tests was the same for the final-test and the same materials and procedures were used. A period of 30 consecutive days elapsed between the base-line and final tests, during which the participants had to ingest their supplement (synbiotic).
Study: NCT03644147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen will be intravenously administrated to treatment group after the end of surgery.
Study: NCT04235595

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Connective Tissue Manipulation
Description: The application was delivered with the participant in a sitting position, with the entire back and sacral regions left exposed. The treatment was administered to the sacral, lower thoracic and pelvic regions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation
Description: TENS was administered with the participant lying face down with a flat cushion underneath the abdomen. TENS was administered via 2 channels of electrodes placed with the sacral region in the middle. The intensity of the current was increased until the participant felt it.
Study: NCT03507491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered intravenously once weekly over 60 minutes every 3 out of four weeks. The dose of gemcitabine will start at 675 mg/m2/dose. If the MTD has been exceeded at the Dose Level 1, then the subsequent cohort of participants will be treated with gemcitabine at a dose of 500 mg/m2/dose (Dose Level 0).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-Paclitaxel will be administered intravenously over 30 minutes once weekly every 3 out of 4 weeks. Nab-paclitaxel will be administered prior to administration of gemcitabine. The starting dose of nab-paclitaxel will be 180 mg/m2/dose (dose level 1). Dose levels for subsequent groups of subjects are 210 mg/m2/dose (for dose level 2) and 240 mg/m2/dose (for dose level 3).
Study: NCT02197481

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Clamp-Crushing technique
Description: Liver transection during hepatectomy by monopole electronicknife and blood vessel forceps, but without BiClamp forceps

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BiClamp forceps
Description: liver transection during hepatectomy by BiClamp forceps
Study: NCT00163657

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daclizumub
Description: anti-rejection drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daclizumub
Description: anti-rejection drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: anti rejection drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: anti rejection drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: anti rejection drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: anti rejection drug
Study: NCT04776772

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: On two separate days, the baseline-tests and final-tests were conducted. All participants performed a series of tests, before which they had to fast. The order and schedule (8 am) of the tests was the same for the final-test and the same materials and procedures were used. A period of 30 consecutive days elapsed between the base-line and final tests, during which the participants had to ingest their supplement (placebo).
Study: NCT00163657

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMF
Description: anti rejection drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMF
Description: anti rejection drug
Study: NCT01972386

Intervention type: DEVICE
Intervention: Spectrum Image Analysis using a Linear Array Ultrasound Bronchoscope
Study: NCT03673670

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPL554 Suspension
Description: A PDE3/4 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPL554 Suspension
Description: A PDE3/4 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: A placebo solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium/olodaterol (Respimat)
Description: An anticholinergic/β-agonist combination medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium/olodaterol (Respimat)
Description: An anticholinergic/β-agonist combination medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium/olodaterol (Respimat)
Description: An anticholinergic/β-agonist combination medication
Study: NCT02146105

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga For Knee Osteoarthritis
Description: Yoga program specifically for women with knee osteoarthritis.
Study: NCT03149874

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis B recombinant DNA vaccine
Description: Hepatitis B recombinant DNA vaccine